Literature DB >> 2946408

Rejection of reovirus-treated L1210 leukemia cells by mice.

M E Williams, D C Cox, J R Stevenson.   

Abstract

L1210 leukemia cells were treated in vitro with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and reovirus to determine their interactive effects on rejection of these tumor cells by mice. The cells were treated with BCNU at concentrations of 0, 3, or 10 microM, incubated for 48 h, then treated with reovirus at a multiplicity of infection of 0, 10, 30, or 100 for 2, 6, or 12 h. The survival of mice injected with cells treated with any amount of reovirus, regardless of BCNU treatment, was greater than that of mice injected with untreated cells. Exposure of the cells to reovirus for 6 or 12 h increased the survival of mice injected with these cells as compared with that of mice injected with cells exposed to reovirus for 2 h. Of the survivors, 76% were resistant to subsequent challenge with untreated L1210 cells. These results suggest that activities associated with reovirus replication may cause modifications of L1210 cells that enable them to induce an immune response, thus facilitating their rejection. A lack of correlation between differences in DNA synthesis (measured by 3H-thymidine uptake) by treated cells and the ability of those cells to kill recipient mice indicates that rejection of cells treated with reovirus or BCNU is not due to a decrease in their ability to proliferate or, presumably, to generate lethal tumors. The survival of mice injected with treated L1210 cell preparations containing as few as 2.9% reovirus-infected cells was enhanced to the same degree as that of mice injected with those containing as many as 14.6% infected cells, indicating that modification of only a minor component of the tumor cell population is sufficient to alter the ability of the cells to generate a lethal tumor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2946408     DOI: 10.1007/bf00199812

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Differential sensitivity of normal and transformed human cells to reovirus infection.

Authors:  M R Duncan; S M Stanish; D C Cox
Journal:  J Virol       Date:  1978-11       Impact factor: 5.103

2.  The induction of interferon by temperature-sensitive mutants of reovirus, UV-irradiated reovirus, and subviral reovirus particles.

Authors:  M H Lai; W K Joklik
Journal:  Virology       Date:  1973-01       Impact factor: 3.616

3.  Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  Nat New Biol       Date:  1972-01-12

4.  Early inhibition of cellular DNA synthesis by high multiplicities of infectious and UV-inactivated Reovirus.

Authors:  J E Shaw; D C Cox
Journal:  J Virol       Date:  1973-10       Impact factor: 5.103

5.  Endotoxin and double stranded RNA render macrophages cytotoxic.

Authors:  P Alexander; R Evans
Journal:  Nat New Biol       Date:  1971-07-21

6.  Natural killer cells: characteristics and regulation of activity.

Authors:  R B Herberman; J Djeu; H D Kay; J R Ortaldo; C Riccardi; G D Bonnard; H T Holden; R Fagnani; A Santoni; P Puccetti
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

7.  DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas.

Authors:  L C Erickson; M O Bradley; J M Ducore; R A Ewig; K W Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Formation of the cross-linked base, diguanylethane, in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea.

Authors:  W P Tong; D B Ludlum
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

9.  The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.

Authors:  M Nagarkatti; A M Kaplan
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

10.  Increased sensitivity of murine leukemia virus-infected tumor cells to lymphocyte-mediated cytotoxicity.

Authors:  M Kasai; H Yamaguchi; M Hosokawa; Y Mizushima; H Kobayashi
Journal:  J Natl Cancer Inst       Date:  1981-08       Impact factor: 13.506

View more
  5 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

3.  Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia.

Authors:  J S Bryson; D C Cox
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 4.  Reovirus receptors, cell entry, and proapoptotic signaling.

Authors:  Pranav Danthi; Geoffrey H Holm; Thilo Stehle; Terence S Dermody
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.